- Home
- Hospitals & Providers
- Eli Lilly and Novo Nordisk fac ...

Both Eli Lilly and Novo Nordisk have recently come under fire after patients using their Type 2 diabetes drugs, tirzepatide and semaglutide, experienced severe gastrointestinal events.
The personal injury lawsuit was brought against the drug by a firm called Morgan & Morgan on the basis that manufacturers failed to warn patients of the possibility of gastroparesis when taking the drug.
Diabetes drug adverse effects lawsuit – Jaclyn Bjorklund’s Case
– Eli Lilly and Novo Nordisk face a lawsuit over adverse effects of their GLP-1 medicines.
– Patients using tirzepatide and semaglutide experienced severe gastrointestinal events.
– The personal injury lawsuit was brought by Morgan & Morgan, alleging failure to warn about gastroparesis risks.
– The case focuses on Jaclyn Bjorklund, a 44-year-old Louisiana woman who used both diabetes drugs.
– Bjorklund suffered severe adverse effects, including excessive vomiting and tooth loss.
– Lawsuit mentions potential gastroparesis and gastroenteritis but diagnosis remains unclear.
– Attorneys Jonathan Sedgh and Paul Pennock lead the lawsuit and intend to file more cases.
– Bjorklund seeks compensation for pain, suffering, attorney fees, and medical expenses.
– Morgan & Morgan investigates around 400 inquiries from patients across 40 states.
Jonathan Sedgh and Paul Pennock are attorneys leading the lawsuit, and Pennock shared in an online conference, “Her (Bjorklund’s) problems have been so severe that she’s been to the emergency room multiple times, including last weekend. She’s actually even thrown up so violently that she’s lost teeth.”
Although Bjorklund has yet to be officially diagnosed with gastroparesis, she is seeking financial compensation for past and future pain and suffering, as well as the cost of the attorney and trial and medical fees incurred during sickness.
In addition to Bjorklund, Morgan & Morgan is also investigating other inquiries of around 400 people across over 40 states.
A Novo Nordisk spokesperson responded to the allegations raised in the lawsuit by stating that gastrointestinal events are commonly recognized side effects of GLP-1 class drugs. They pointed out that both Ozempic and Mounjaro’s prescribing labels already caution about the potential risk of gastrointestinal adverse reactions and explicitly mention the possibility of delayed gastric emptying.
For semaglutide, the spokesperson has explained that adverse reactions should not be too long-lasting and only moderate in severity. The statement also explained how there are other risk factors for gastroparesis, including obesity, nervous system disorders, and viral infections. Women also happen to be more prone to contracting the disease.
Novo has also brought attention to the fact that its drug has patient exposure of over 9.5 million over the years. The safety profile of the drug has been tested in large real-world evidence studies.
A Lilly spokesperson has also responded to the allegations by saying that the company frequently engages in monitoring and evaluating the safety information of its medication, and both firms have said that patient safety is a top priority for them.